O	0	4	Long
O	4	5	-
O	5	9	term
O	10	17	effects
O	18	20	on
O	21	24	the
O	25	34	incidence
O	35	37	of
O	38	44	second
O	45	52	primary
O	53	60	cancers
O	61	63	in
O	64	65	a
O	66	76	randomized
O	77	82	trial
O	83	85	of
O	86	89	two
O	90	93	and
O	94	98	five
O	99	104	years
O	105	107	of
O	108	116	adjuvant
B-intervention	117	126	tamoxifen
O	126	127	.

O	128	137	Tamoxifen
O	138	140	is
O	141	142	a
O	143	147	well
O	148	159	established
O	160	169	treatment
O	170	173	for
O	174	180	breast
O	181	187	cancer
O	187	188	,
O	189	192	but
O	193	196	its
O	197	201	long
O	201	202	-
O	202	206	term
O	207	214	effects
O	215	217	on
O	218	221	the
O	222	231	incidence
O	232	234	of
O	235	244	secondary
O	245	252	cancers
O	253	256	are
O	257	260	not
O	261	266	fully
O	267	276	evaluated
O	276	277	.

O	278	280	We
O	281	285	have
O	286	293	studied
B-total-participants	294	298	4128
B-eligibility	299	313	postmenopausal
I-eligibility	314	322	patients
I-eligibility	323	327	with
I-eligibility	328	333	early
I-eligibility	334	339	stage
I-eligibility	340	346	breast
I-eligibility	347	353	cancer
I-eligibility	354	357	who
I-eligibility	358	362	were
I-eligibility	363	368	alive
I-eligibility	369	372	and
I-eligibility	373	377	free
I-eligibility	378	380	of
I-eligibility	381	387	breast
I-eligibility	388	394	cancer
I-eligibility	395	405	recurrence
I-eligibility	406	411	after
I-eligibility	412	415	two
I-eligibility	416	421	years
I-eligibility	422	424	of
I-eligibility	425	434	tamoxifen
O	434	435	,
O	436	439	and
O	440	443	who
O	444	448	were
O	449	459	randomized
O	460	462	to
O	463	470	receive
O	471	478	totally
O	479	482	two
O	483	485	or
O	486	490	five
O	491	496	years
O	497	499	of
O	500	507	therapy
O	507	508	.

O	509	517	Compared
O	518	520	to
O	521	529	patients
O	530	540	randomized
O	541	543	to
O	544	547	two
O	548	553	years
O	554	556	of
O	557	566	tamoxifen
O	567	570	the
B-outcome	571	580	incidence
I-outcome	581	583	of
I-outcome	584	597	contralateral
I-outcome	598	604	breast
I-outcome	605	611	cancer
O	612	613	[
O	613	619	hazard
O	620	625	ratio
O	626	627	(
O	627	629	HR
O	629	630	)
O	631	632	0
O	632	633	.
O	633	635	73
O	635	636	;
O	637	639	95
O	639	640	%
O	641	643	CI
O	644	645	0
O	645	646	.
O	646	648	56
O	648	649	-
O	649	650	0
O	650	651	.
O	651	653	96
O	653	654	]
O	655	658	and
O	659	661	of
B-outcome	662	666	lung
I-outcome	667	673	cancer
O	674	675	(
O	675	677	HR
O	678	679	0
O	679	680	.
O	680	682	45
O	682	683	;
O	684	686	95
O	686	687	%
O	688	690	CI
O	691	692	0
O	692	693	.
O	693	695	27
O	695	696	-
O	696	697	0
O	697	698	.
O	698	700	77
O	700	701	)
O	701	702	,
O	703	713	especially
O	714	722	squamous
O	723	727	cell
O	728	731	and
O	732	737	small
O	738	742	cell
O	743	747	lung
O	748	754	cancer
O	754	755	,
O	756	760	were
O	761	768	reduced
O	769	771	in
O	772	775	the
O	776	780	five
O	780	781	-
O	781	785	year
O	786	791	group
O	791	792	,
O	793	796	and
O	797	804	similar
O	805	812	results
O	813	817	were
O	818	822	seen
O	823	827	when
O	828	839	restricting
O	840	843	the
O	844	852	analysis
O	853	855	to
O	856	859	the
O	860	862	10
O	862	863	-
O	863	867	year
O	868	874	period
O	875	880	after
O	881	890	treatment
O	891	898	stopped
O	898	899	.

O	900	902	An
O	903	912	increased
B-outcome	913	922	incidence
I-outcome	923	925	of
I-outcome	926	937	endometrial
I-outcome	938	944	cancer
O	945	948	was
O	949	957	observed
O	958	960	in
O	961	964	the
O	965	969	five
O	969	970	-
O	970	974	year
O	975	980	group
O	980	981	,
O	982	985	but
O	986	989	the
O	990	996	excess
O	997	1001	risk
O	1002	1011	decreased
O	1012	1016	over
O	1017	1021	time
O	1021	1022	.

O	1023	1030	Further
O	1031	1038	studies
O	1039	1041	of
O	1042	1045	the
O	1046	1053	effects
O	1054	1056	of
O	1057	1066	tamoxifen
O	1067	1069	on
O	1070	1073	the
O	1074	1078	risk
O	1079	1081	of
O	1082	1091	different
O	1092	1104	histological
O	1105	1110	types
O	1111	1113	of
O	1114	1118	lung
O	1119	1125	cancer
O	1126	1129	are
O	1130	1136	needed
O	1136	1137	.
